Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 230 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR Όροι χρήσης και προϋποθέσεις January 18, 2019 FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated... October 13, 2022 What Cancer Survivors Should Know About Survivorship Research: Expert Perspectives January 26, 2024 Preparing for the End of the U.S. Public Health Emergency (PHE):... February 13, 2023 Load more HOT NEWS Neoadjuvant Docetaxel, Oxaliplatin, and S-1, as Part of Perioperative Chemotherapy, Prolongs... No OS Benefit in EGFR T790M Advanced NSCLC Treated with Osimertinib... TG4001 Therapeutic Vaccination Plus Avelumab-Mediated PD-L1 Blockade Improves Tumour Microenvironment in... Promising Results Are Provided by Tebentafusp in Metastatic Uveal Melanoma
